120 related articles for article (PubMed ID: 10461447)
1. [Prognostic value of the presence of the mutation of the codons 12, 13 and 61 in K-ras oncogene in colorectal cancer].
Pajkos G; Kiss I; Sándor J; Ember I; Kisházi P
Orv Hetil; 1999 Jul; 140(30):1673-9. PubMed ID: 10461447
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer.
Pajkos G; Kiss I; Sándor J; Ember I; Kisházi P
Anticancer Res; 2000; 20(3A):1695-701. PubMed ID: 10928094
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality.
Al-Mulla F; Going JJ; Sowden ET; Winter A; Pickford IR; Birnie GD
J Pathol; 1998 Jun; 185(2):130-8. PubMed ID: 9713338
[TBL] [Abstract][Full Text] [Related]
4. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers.
Lee JC; Wang ST; Lai MD; Lin YJ; Yang HB
Anticancer Res; 1996; 16(6B):3839-44. PubMed ID: 9042267
[TBL] [Abstract][Full Text] [Related]
5. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
[TBL] [Abstract][Full Text] [Related]
6. [Frequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancer].
Estrada P; Rojas-Atencio A; Zabala W; Borjas L; Soca L; Urdaneta K; Alvarez-Nava F; Cañizales J; Rojas J; Soto M
Invest Clin; 2009 Mar; 50(1):55-63. PubMed ID: 19418727
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the eastern cooperative oncology group (EST 2292).
Wadler S; Bajaj R; Neuberg D; Agarwal V; Haynes H; Benson AB
Cancer J Sci Am; 1997; 3(5):284-8. PubMed ID: 9327152
[TBL] [Abstract][Full Text] [Related]
8. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
[TBL] [Abstract][Full Text] [Related]
9. Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report.
Sameer AS; Chowdhri NA; Abdullah S; Shah ZA; Siddiqi MA
Indian J Cancer; 2009; 46(3):219-25. PubMed ID: 19574674
[TBL] [Abstract][Full Text] [Related]
10. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
[TBL] [Abstract][Full Text] [Related]
11. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer.
Arango D; Laiho P; Kokko A; Alhopuro P; Sammalkorpi H; Salovaara R; Nicorici D; Hautaniemi S; Alazzouzi H; Mecklin JP; Järvinen H; Hemminki A; Astola J; Schwartz S; Aaltonen LA
Gastroenterology; 2005 Sep; 129(3):874-84. PubMed ID: 16143127
[TBL] [Abstract][Full Text] [Related]
12. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of p53, K-ras and DCC gene alterations in the stage I-II colorectal cancers.
Akkiprik M; Ataizi-Celikel C; Düşünceli F; Sönmez O; Gulluoglu BM; Sav A; Ozer A
J Gastrointestin Liver Dis; 2007 Mar; 16(1):11-7. PubMed ID: 17410283
[TBL] [Abstract][Full Text] [Related]
14. Genotyping of p53 codon 175 in colorectal cancer.
Krajewska WM; Stawińska M; Bryś M; Młynarski W; Witas HW; Okruszek A; Kiliańska ZM
Med Sci Monit; 2003 May; 9(5):BR188-91. PubMed ID: 12761448
[TBL] [Abstract][Full Text] [Related]
15. Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer.
Zulhabri O; Rahman J; Ismail S; Isa MR; Wan Zurinah WN
Singapore Med J; 2012 Jan; 53(1):26-31. PubMed ID: 22252179
[TBL] [Abstract][Full Text] [Related]
16. K-ras codon 12 and 13 mutations are correlated with differential patterns of tumor cell dissemination in colorectal cancer patients.
Conzelmann M; Linnemann U; Berger MR
Int J Oncol; 2004 Jun; 24(6):1537-44. PubMed ID: 15138598
[TBL] [Abstract][Full Text] [Related]
17. Reappraisal of K-ras and p53 gene mutations in the recurrence of Dukes' B2 rectal cancer after curative resection.
Liang JT; Cheng YM; Chang KJ; Chien CT; Hsu HC
Hepatogastroenterology; 1999; 46(26):830-7. PubMed ID: 10370622
[TBL] [Abstract][Full Text] [Related]
18. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases.
Petrowsky H; Sturm I; Graubitz O; Kooby DA; Staib-Sebler E; Gog C; Köhne CH; Hillebrand T; Daniel PT; Fong Y; Lorenz M
Eur J Surg Oncol; 2001 Feb; 27(1):80-7. PubMed ID: 11237496
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer.
Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D
J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
